The post XRP on Verge of Ultra-Rare Golden Cross Versus Bitcoin appeared on BitcoinEthereumNews.com. It may all finally change for one of the most closely watched alternative trading pairs on the crypto market — XRP/BTC. For years, the XRP/BTC chart has tended to remain in a downtrend against Bitcoin. Even the latest 300% rally did not push XRP to even 30% of what was once its all-time high in this pair, at 0.000245 BTC per XRP back in May 2017. However, the current picture is starting to look different. On both the weekly and monthly charts, XRP is entering an area where the 23-period moving average is about to cross above the 50-period moving average. This formation is known as a golden cross.  The last time it appeared on the XRP/BTC chart, it coincided with a 112% increase from November 2024 to February 2025. XRP/BTC by TradingView If confirmed, the most probable short-to-medium-term target is a retest of 0.00004 BTC. This would represent a 60% increase from current levels and align with the resistance level from the late 2022 consolidation period.  Scenarios Breaking above 0.00005 BTC would open the door to the wider 0.00007-0.00008 BTC range, where there is heavy supply from the 2021-2022 cycle. For the XRP price, in dollar terms, this would mean a range of $4.76-$9.51.  Add the fact that Oct. 18, which is two weeks away, is the deadline date for a spot XRP ETF, and it looks like the perfect combination. Whether this scenario will come to life, though, is an open question. Source: https://u.today/xrp-on-verge-of-ultra-rare-golden-cross-versus-bitcoin-1The post XRP on Verge of Ultra-Rare Golden Cross Versus Bitcoin appeared on BitcoinEthereumNews.com. It may all finally change for one of the most closely watched alternative trading pairs on the crypto market — XRP/BTC. For years, the XRP/BTC chart has tended to remain in a downtrend against Bitcoin. Even the latest 300% rally did not push XRP to even 30% of what was once its all-time high in this pair, at 0.000245 BTC per XRP back in May 2017. However, the current picture is starting to look different. On both the weekly and monthly charts, XRP is entering an area where the 23-period moving average is about to cross above the 50-period moving average. This formation is known as a golden cross.  The last time it appeared on the XRP/BTC chart, it coincided with a 112% increase from November 2024 to February 2025. XRP/BTC by TradingView If confirmed, the most probable short-to-medium-term target is a retest of 0.00004 BTC. This would represent a 60% increase from current levels and align with the resistance level from the late 2022 consolidation period.  Scenarios Breaking above 0.00005 BTC would open the door to the wider 0.00007-0.00008 BTC range, where there is heavy supply from the 2021-2022 cycle. For the XRP price, in dollar terms, this would mean a range of $4.76-$9.51.  Add the fact that Oct. 18, which is two weeks away, is the deadline date for a spot XRP ETF, and it looks like the perfect combination. Whether this scenario will come to life, though, is an open question. Source: https://u.today/xrp-on-verge-of-ultra-rare-golden-cross-versus-bitcoin-1

XRP on Verge of Ultra-Rare Golden Cross Versus Bitcoin

It may all finally change for one of the most closely watched alternative trading pairs on the crypto market — XRP/BTC. For years, the XRP/BTC chart has tended to remain in a downtrend against Bitcoin. Even the latest 300% rally did not push XRP to even 30% of what was once its all-time high in this pair, at 0.000245 BTC per XRP back in May 2017.

However, the current picture is starting to look different. On both the weekly and monthly charts, XRP is entering an area where the 23-period moving average is about to cross above the 50-period moving average. This formation is known as a golden cross. 

The last time it appeared on the XRP/BTC chart, it coincided with a 112% increase from November 2024 to February 2025.

XRP/BTC by TradingView

If confirmed, the most probable short-to-medium-term target is a retest of 0.00004 BTC. This would represent a 60% increase from current levels and align with the resistance level from the late 2022 consolidation period. 

Scenarios

Breaking above 0.00005 BTC would open the door to the wider 0.00007-0.00008 BTC range, where there is heavy supply from the 2021-2022 cycle. For the XRP price, in dollar terms, this would mean a range of $4.76-$9.51. 

Add the fact that Oct. 18, which is two weeks away, is the deadline date for a spot XRP ETF, and it looks like the perfect combination. Whether this scenario will come to life, though, is an open question.

Source: https://u.today/xrp-on-verge-of-ultra-rare-golden-cross-versus-bitcoin-1

Market Opportunity
XRP Logo
XRP Price(XRP)
$2.0702
$2.0702$2.0702
-1.25%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26